ARWR vs IDYA

Arrowhead Pharmaceuticals maintains strong 10x growth potential within 3-5 years, leveraging its advanced TRiM RNAi platform and a robust pipeline targeting high-value indications. The positive Phase 3 data for ARO-AAT (fazirsiran) in Alpha-1 Antitrypsin Deficiency, recently announced (Q4 2025/early Q1 2026), remains a pivotal catalyst, positioning the company for imminent regulatory submission an...

IDEAYA Biosciences maintains a strong score, reflecting its pioneering role in synthetic lethality oncology, a field with immense unmet needs and significant market potential. The robust GSK partnership continues to validate its platform, providing critical non-dilutive funding and extending cash runway, which is vital for an early-stage biotech. Clinical programs like darovasertib (uveal melanoma...